Key facts
- Ablative Solutions’s last known valuation is $140.0M (Jun 2022).
- It has raised $214.6M across 4 recorded rounds; the latest was Early Stage VC ($10.4M) in Nov 2025.
- Notable investors include Invus Opportunities, Gilde Healthcare, BioStar Capital, CKM Capital, Charter Private Capital Management — 11 tracked in total.
- Ablative Solutions has filed 3 Form Ds with the SEC since 2021, most recently Dec 2024 ($37.2M sold to 88 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Ablative Solutions
Funding rounds
4 roundsAbout Ablative Solutions
Developer of catheter-based neurolytic delivery systems designed for therapeutic intervention in hypertension. The company's platform incorporates a proprietary infusion catheter equipped with guided microneedles that deliver neurolytic agents into the perivascular space surrounding renal arteries, enabling healthcare providers to perform targeted renal denervation procedures with fluoroscopic guidance, minimal invasiveness, and enhanced anatomical precision to address treatment-resistant high blood pressure.
- Sector
- Healthcare
- HQ
- Wakefield, MA, United States
- Founded
- 2011
- Employees
- 19
- Website
- ablativesolutions.com/
- Ownership
- Privately Held (backing)
Ablative Solutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ablative Solutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ablative Solutions in its N-PORT filings yet. We sweep new filings monthly.